GlaxoSmithKline

European Commission expands Jemperli (dostarlimab) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer

20 Jan 2025

Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases.

20 January 2025

20 Jan 2025

Expanded approval includes MMRp/MSS tumours, which represent approximately 75% of endometrial cancer cases.

GSK enters agreement to acquire IDRx, Inc.

13 Jan 2025

Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers

13 January 2025

13 Jan 2025

Acquisition adds to GSK’s growing portfolio in gastrointestinal (GI) cancers

19 December 2016

11 Jan 2025

Healthcare workers among those to be vaccinated in large-scale trial involving up to 30,000 people due to start in the coming weeks

GSK announces Board changes

11 Jan 2025

The creation of a new Board committee and a number of changes to the membership of the Board and its committees

ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen

11 Jan 2025

First phase III studies to show efficacy of two-drug regimen as maintenance therapy

GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older

11 Jan 2025

An approval from the US Food and Drug Administration’s (FDA) Center

GSK announces positive results in fourth consecutive pivotal trial of Benlysta® (belimumab) in SLE

11 Jan 2025

Data in Japan, China and South Korea will form basis of new regulatory submissions for Benlysta

GSK statement in response to New York Times article on China

11 Jan 2025

These matters relating to our operations in China were deeply disappointing to GSK.

View details about the software product Informachine News Trackers